Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a case report.
AANA Journal
|June 7, 2014
Summary
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) offers improved survival for peritoneal cancer patients. Anesthetic management is crucial due to potential complications during this complex oncologic procedure.
Area of Science:
- Oncology
- Surgical Oncology
- Anesthesiology
Background:
- Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment for cancers with peritoneal metastasis.
- The peritoneal surface is a common site for treatment failure in gynecologic and gastrointestinal cancers.
- Historically, advanced cancer patients received palliative care or no surgical intervention.
Observation:
- This case report details the treatment of a 71-year-old woman with stage III peritoneal and ovarian cancer.
- The patient underwent cytoreductive surgery combined with HIPEC.
- Anesthetic management during HIPEC requires careful attention to hemodynamics, coagulation, and respiratory function.
Findings:
- Cytoreductive surgery with HIPEC has demonstrated increased survival rates for patients with peritoneal cancer.
- Anesthetic complications, including hemodynamic instability, coagulation disturbances, and respiratory compromise, are frequently observed.
- Anticipating and managing these anesthetic challenges is key to successful patient outcomes.
Implications:
- HIPEC represents a significant advancement for patients with advanced peritoneal disease, offering a potentially curative option.
- Understanding and preparing for anesthetic complexities associated with HIPEC is vital for surgical teams.
- This approach may shift treatment paradigms for advanced cancers involving the peritoneum.
